Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.

CONCLUSIONS: These findings suggest that the JAK2V617F mutation can alter vascular endothelial function to promote cardiovascular complications in MPNs. Therefore, targeting the MPN vasculature represents a promising new therapeutic strategy for patients with MPNs.
PMID: 32920974 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - September 12, 2020 Category: Hematology Authors: Castiglione M, Jiang YP, Mazzeo C, Lee S, Chen JS, Kaushansky K, Yin W, Lin RZ, Zheng H, Zhan H Tags: J Thromb Haemost Source Type: research